AMCP 2023

Inflation Reduction Act (IRA) Implementation: Inflation-based rebates, Medicare price negotiation, Part D benefit design, and other IRA policies will have a profound impact on healthcare stakeholders. Avalere can help evaluate these policies’ effects and develop strategies for product development and investment decisions, manufacturer contracting strategies, plan formulary and benefit design, and ensuring patient access to medications.

Rethinking Evidence and Value Communication: The IRA is amplifying focus on the value of medication, increasing the need for all healthcare stakeholders to consider innovative approaches to evidence generation and the measurement of value. Our experts can share perspectives from the lens of policy, payer, and life sciences to provide insights on how anticipated market changes will drive behavioral changes across key stakeholders as they make decisions to maintain their business.

Part D Redesign Strategy and Modeling: Part D benefit redesign will add pressure to plans and manufacturers, while increasing affordability for beneficiaries. Manufacturers can expect Part D volume and revenue changes and should prepare for new plan approaches to formulary and benefit design. Avalere can be a thought partner to manufacturers developing their strategy for engaging Part D plans for 2025 using qualitative and quantitative approaches.